glp-1 origin Glucagon-Like Peptide-1: New Regulator in Lipid Metabolism Central glucagon-like peptide 1 receptor

Importantly, patients prefer, and are more likely to adhere to, an oral drug regimen versus an injectable alternative

The medication can open the door, but daily habits are what help you keep walking through it

Semaglutide among Type 2 diabetes patients had the target dose of 1.0 mg granted permission by FDA in 2017 and EMA in 2018

"FDA approves new treatment for rare form of thyroid cancer" (Press release)

Cardiovascular Protection: Major clinical trials like the LEADER trial for liraglutide have shown that GLP-1 RAs can significantly reduce the risk of major adverse cardiovascular events, such as heart attacks and strokes, in patients with type 2 diabetes

Slow dosage increases during close follow-up appointments help patients and clinicians address symptoms promptly